Bladder Cancer

Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers.

After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.

The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.

The FDA has granted approval to pembrolizumab (Keytruda) in the first- and second-line settings for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Treatment with intravesical gemcitabine following surgery reduced the risk of recurrence in patients with low-grade non–muscle invasive bladder cancer.

This video examines second-line treatment options for non-muscle invasive bladder cancer patients who relapse after BCG therapy and are not eligible for radical cystectomy.

New studies at the AUA Annual Meeting highlight the links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.

The FDA has granted accelerated approval to avelumab (Bavencio) for treating locally advanced or metastatic urothelial carcinoma patients whose disease progressed following treatment with platinum-containing chemotherapy.

The FDA has approved durvalumab (Imfinzi) for the treatment of patients with advanced urothelial carcinoma whose disease has progressed after treatment with platinum-containing chemotherapy.

The FDA has expanded its approval of atezolizumab (Tecentriq) for the treatment of advanced bladder cancer to include the initial therapy of patients who are not eligible for cisplatin chemotherapy.

This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.

The PD-L1 antibody avelumab was well tolerated and had promising antitumor activity in patients with refractory metastatic urothelial carcinoma.

Maintenance vinflunine yielded longer progression-free survival vs best supportive care in advanced urothelial carcinoma patients after disease control with chemotherapy.

Sorafenib, gemcitabine, and cisplatin had promising activity and was well tolerated in patients with muscle-invasive urothelial bladder cancer.

Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.

Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

In this interview we discuss the latest clinical news in urothelial carcinoma, what we’ve learned about the biology of these tumors, and how treatment of this disease has evolved.

Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.

The PD-1 inhibitor pembrolizumab yielded significantly improved overall survival vs chemotherapy as second-line treatment in advanced urothelial cancer.

We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.

The PD-1 inhibitor pembrolizumab showed promising antitumor activity and acceptable safety in patients with advanced urothelial cancer, in a phase I trial.

In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.